Literature DB >> 16001389

Combined surgical ablation and intravitreal triamcinolone acetonide for retinal angiomatous proliferation.

F Boscia1, C Furino, F Prascina, N Delle Noci, L Sborgia, C Sborgia.   

Abstract

PURPOSE: Neovascular age-related macular degeneration (ARMD) with retinal angiomatous proliferation (RAP) has a poor natural history and the efficacy of any treatment has not yet been established. The authors describe a combined surgical treatment.
METHODS: A 76-year-old woman presented with a best-corrected visual acuity (BCVA) of 20/600 in the right eye and macula with stage 3 RAP as identified by fluorescein angiography (FA), indocyanine green angiography (ICGA), and optical coherence tomography (OCT). After a standard three-port pars plana core vitrectomy (PPV), endodiathermy of the arteriolar and venous feeder vessels of each lesion was performed, intraretinal RAP feeder vessels were cut with manual vertical intraocular scissors, and 0.1 mL of triamcinolone acetonide (TAAC) was injected intravitreally. At 1 and 4 weeks and at the sixth month, the patient underwent a complete eye examination, FA, ICGA, and OCT to assess outcomes and complications.
RESULTS: Six months later, BCVA was stable at 20/300, intraocular pressure was 15 mmHg, anterior segment and vitreous cavity were clear without evidence of TAAC granules, and retina was attached. FA and ICGA showed a complete occlusion of the RAP and absence of leakage or ischemia and OCT demonstrated decreased macular thickness with resolution of both intraretinal edema and pigment epithelium detachment, and the restoration of the normal macular profile. At the end of follow-up, the authors did not observe any ocular or systemic complication.
CONCLUSIONS: Surgical approach to RAP stage 3 with intravitreal injection of 4 mg of TAAC was safe and anatomically effective.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16001389     DOI: 10.1177/112067210501500418

Source DB:  PubMed          Journal:  Eur J Ophthalmol        ISSN: 1120-6721            Impact factor:   2.597


  8 in total

1.  [Therapy of stage III retinal angiomatous proliferation. Intravitreal ranibizumab injections].

Authors:  M Maier; C Perz; J Bockmaier; N Feucht; C P Lohmann
Journal:  Ophthalmologe       Date:  2013-12       Impact factor: 1.059

2.  [Intravitreal ranibizumab for the treatment of retinal angiomatous proliferation].

Authors:  J Maaß; D Sandner; E Matthé
Journal:  Ophthalmologe       Date:  2017-06       Impact factor: 1.059

3.  Intravitreal triamcinolone and laser photocoagulation for retinal angiomatous proliferation.

Authors:  T R Krieglstein; A Kampik; M Ulbig
Journal:  Br J Ophthalmol       Date:  2006-08-02       Impact factor: 4.638

4.  Intravitreal ranibizumab (Lucentis) in the treatment of retinal angiomatous proliferation (RAP).

Authors:  Lazaros Konstantinidis; Evangelia Mameletzi; Irmela Mantel; Jean-Antoine Pournaras; Leonidas Zografos; Aude Ambresin
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-04-29       Impact factor: 3.117

5.  [Anti-VEGF treatment for retinal angiomatous proliferation].

Authors:  A Wolf; D Kook; T Kreutzer; A Gandorfer; C Haritoglou; A Kampik; M Ulbig
Journal:  Ophthalmologe       Date:  2008-09       Impact factor: 1.059

6.  Ranibizumab in monotherapy and combined with photodynamic therapy for retinal angiomatous proliferation.

Authors:  Luis Arias; Francisco Gómez-Ulla; José M Ruiz-Moreno
Journal:  Clin Ophthalmol       Date:  2016-05-17

7.  Comprehensive analysis of inflammatory immune mediators of the intraocular fluid aspirated from the foldable capsular vitreous body filled-eyes.

Authors:  Peijuan Wang; Qianying Gao; Xiaofeng Lin; Shaochong Zhang; Jie Hu; Yaqin Liu; Nuo Xu; Jian Ge
Journal:  PLoS One       Date:  2012-10-01       Impact factor: 3.240

8.  Retinal angiomatous proliferation and intravitreal bevacizumab injection.

Authors:  Jae Hoon Kang; Kyung Ah Park; Song Ee Chung; Se Woong Kang
Journal:  Korean J Ophthalmol       Date:  2007-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.